• About
  • Services
  • Clients
  • Client News
  • PCG Research
  • PCG Digital
  • Contact
  • follow:

  • 25 Jun

    PCG Research Announces Publication of Update Report Covering Zomedica Pharmaceuticals Corp.

    Diagnostic Commercialization Activities for the Companion Animal Market Approaching New York, New York--(Newsfile Corp. - June 25, 2020) - PCG Research, the equity research division of PCG Advisory, Inc., a leading investor relations and strategic advisory firm based in New York City focused on small and micro-cap public companies, today… Read More..

    Share this:
  • 24 Jun

    Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis

    Final top-line results expected Q4 2020 PRINCETON, N.J., June 24, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has completed patient enrollment in… Read More..

    Share this:
  • 23 Jun

    Targeting The National Cancer Institute’s #1- Ranked Cancer Antigen: SELLAS’ Most Advanced Immunotherapy in Pivotal Phase 3 Study in AML and in Phase 1/2 Studies in Combination With PD1

    New York, New York--(Newsfile Corp. - June 23, 2020) - As the United States enters nearly its fifth month in the global fight against COVID-19, many investors have set their eyes on companies racing to discover a cure and restore things back to a sense of normalcy. But despite this… Read More..

    Share this:
« Previous 1 … 181 182 183 184 185 … 295 Next »
  • Twitter feed is not available at the moment.
  • QUICK LINKS

    • About
    • Services
    • Clients
    • Client Media
    • PCG Media
    • PCG Research
    • Contact
    • Privacy Policy
    • Disclosures

    FOLLOW US

    Copyright © 2022 PCG Advisory.

    MENU logo
    • About
    • Services
    • Clients
    • Client News
    • PCG Research
    • PCG Digital
    • Contact